|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
Crusting inside nose or epistaxis |
|
sore throat |
|
ulceration of nasal mucosa |
|
Cough |
|
dizziness or light-headedness |
|
hoarseness |
|
lethargy |
|
loss of sense of taste or smell |
|
nausea or vomiting |
|
rhinorrhea, continuing |
|
stuffy nose, continuing |
|
watery eyes, continuing |
|
stomach pains |
|
Nasal candidiasis |
|
nasal septal perforation |
|
ocular hypertension |
|
pharyngeal candidiasis |
|
Dermatitis |
|
urticaria |
|
Acneiform lesions |
|
Cushing's syndrome |
|
menstrual changes |
|
Burning, dryness, or other irritation inside the nose, mild and transient |
|
Sneezing |
|
Throat itching |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Amebiasis, latent or active |
|
Asthma |
|
Glaucoma |
|
Hepatic function impairment |
|
Hypothyroidism |
|
>> Infections, fungal, bacterial, |
|
>> Ocular herpes simplex |
|
Nasal septal ulcers, recent |
|
Nasal surgery, recent |
|
Nasal trauma, recent |
|
>> Tuberculosis, latent or active, of respiratory tract |
|
|
ADULT DOSE:
|
|
Anti-Inflammatory (steroidal), nasal-Initial: Nasal, 64 mcg (0.064 mg) (2 metered sprays) in each nostril twice a day or 128 mcg (0.128 mg) (4 metered sprays) in each nostril once a day (total daily dose, 256 mcg [0.256 mg]). |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Anti-inflammatory (steroidal), nasal-Children up to 6 years of age: Safety and efficacy have not been established.
Children 6 years of age and older: See Usual adult and adolescent dose .
Note: [Children 4 to 6 years of age] have benefited from 100 mcg (1 metered inhalation) to 200 mcg (2 metered inhalations) in each nostril daily, up to 400 mcg (4 metered inhalations total) daily, followed by a dosage adjusted to the lowest effective dose as determined by the child's response. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|